All the news

Showing 10 of 676 articles from: Therapies

Show

High Demand for New HCV Drugs Could Cause Ethical Problems

Medscape / 31 May 2011
NICE to appraise hep C drugs Victrelis and telaprevir

InPharm / 26 May 2011
Achillion Announces Initiation of Phase 1 Trial of ACH-2684 for the Treatment of Hepatitis C

Achillion / 26 May 2011
US approval for hepatitis C drug telaprevir

Keith Alcorn / 23 May 2011

The US Food and Drug Administration has approved a new hepatitis C drug telaprevir (Incivek), the agency announced today. Telaprevir is a direct-acting antiviral drug (an HCV protease inhibitor), licensed for use in combination ...
European approval recommended for hepatitis C drug boceprevir

Keith Alcorn / 23 May 2011

The European Medicines Agency has recommended marketing approval for Merck’s hepatitis C protease inhibitor boceprevir (Victrelis), the agency announced on May 20th. Boceprevir is the first direct-acting antiviral agent for hepatitis C to be ...
European approval for new hepatitis C drug boceprevir (Victrelis)

European Medicines Agency / 20 May 2011
The Fair Pricing Coalition Expresses Dismay at the Price of Merck's Newly Approved Hepatitis C Drug

Thebody.com / 18 May 2011
Merck, Roche to Work Together on Hepatitis C Treatments

San Francisco Chronicle / 18 May 2011
Getting Ready; Telaprevir or Boceprevir ?

HCV New Drugs Research / 18 May 2011
Merck’s Hepatitis C Drug Wins F.D.A. Approval

New York Times / 16 May 2011